Uveal Melanoma Market

Introduction Uveal Melanoma : • As the tumor enlarges, it may cause distortion of the pupil (iris melanoma), blurred vision (Ciliary body melanoma), or markedly decreased visual acuity caused by secondary retinal detachment (choroidal melanoma). DelveInsight © 2018 | All rights reserved

Misdiagnoses occur in less than 4% of enucleated eyes at tertiary referral centers. The diagnostic error rate in the Collaborative Ocular Melanoma Study (COMS) was only 0.48%. DIAGNOSIS The diagnostic error rate in the COMS, however, was measured under ideal conditions; all tumors were well visualized and photographed. In real-world situations, the misdiagnosis rate for posterior melanoma may be greater than that reported by the Collaborative Ocular Melanoma Study DelveInsight © 2018 | All rights reserved

Aspects Covered in the Report The report covers the descriptive overview of Uveal Melanoma explaining its pathophysiology, disease classification, diagnostic approaches and treatment algorithm • The report provides the understanding of the future competition in Uveal Melanoma by reviewing the market drivers and barriers 05 01 04 02 The report also reviews the detailed historical and forecasted Uveal Melanoma market size covering the drug outreach in 7MM The report provides the insight into the epidemiology of the disease and its treatment in the 7 MM 03 The report is a comprehensive account of both the current and emerging therapies covering the impact of the new therapies on the current treatment landscape DelveInsight © 2018 | All rights reserved

Market Insight • Despite of Uveal Melanoma’s effective primary therapy, nearly 50% of patients develop metastatic disease. • Several palliative treatments for UM offered in the US and Europe include Liverdirected treatments- Trans arterial Catheter and Immunotherapy, targeted therapy. • As per National Cancer Institute, the mean age-adjusted incidence of Uveal melanoma in the United States is approximately xxx new cases per million people, with no clear variation by latitude • Despite usual success in achieving local control, outcomes for patients with metastatic disease remains impoverished. • h DelveInsight © 2018 | All rights reserved

Services Offered at DelveInsight • Market Size • Market Dynamics • Market Assessment • Trends Analysis • Physicians & Patients Perception • KOLs • Asset Prioritization • Brand Optimization • Portfolio expansion access over 3000+ reports • Therapeutic Assessment • Drug Sales Forecast • Indication Forecast • Clinical Trials Tracking • Competitive landscape • Clinical Trials • Primary Analytics • News-Letters • Conference Tracking • API • Market & Pipeline • Epidemiology • Market Access • Partnership DelveInsight © 2018 | All rights reserved

Uveal Melanoma Market

Télécharger la présentation

Plus de contenu associé